Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
26 hedge funds and large institutions have $42.1M invested in Astria Therapeutics in 2016 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 8 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
1.04% more ownership
Funds ownership: 0% → 1.04% (+1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
16% less funds holding
Funds holding: 31 → 26 (-5)
41% less capital invested
Capital invested by funds: $70.9M → $42.1M (-$28.7M)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.25M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$204K |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$203K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$109K |
| 5 |
Goldman Sachs
New York
|
+$51.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$741K |
| 2 |
TG
TLP Group
Evanston,
Illinois
|
-$160K |
| 3 |
FAM
Fred Alger Management
New York
|
-$153K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$144K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$123K |
ATXS Hedge Fund Activity: Q4 2016 in Review
26 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q4 2016, worth a combined $42.1M — down 41% from $70.9M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ATXS and 3 opened new positions — a net loss of 5 holders — while 5 trimmed existing stakes and 8 added.
The largest buyer was Great Point Partners, adding an estimated $1.25M. The largest seller was Putnam Investments, exiting entirely with an estimated $741K sold.
- 26 institutional investors held Astria Therapeutics (ATXS) as of Q4 2016, down from 31 in Q3 2016.
- Funds reported $42.1M of Astria Therapeutics stock for Q4 2016, down 41% quarter-over-quarter.
- 3 funds opened new Astria Therapeutics positions in Q4 2016 and 8 closed out, a net change of -5 holders.
- The largest Astria Therapeutics buyer in Q4 2016 was Great Point Partners, an estimated $1.25M added.
- The largest Astria Therapeutics seller in Q4 2016 was Putnam Investments, an estimated $741K sold.
Based on aggregated 13F filings for Q4 2016.